Physician profile
Yolanda C Holmes
NPI 1447336045
$79,878.60
in general payments reported to CMS, 2019-2025
41 companies · $2,848 in 2025
The $2,848 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $14K · 2021: $29K · 2022: $1,994 · 2023: $5,607 · 2024: $3,346 · 2025: $2,848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,614 · Consulting Fee: $2,000 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,613.58 |
| Consulting Fee | $2,000.00 |
| Education | $186.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $49,212.23 | 2019-2025 | Absorica Ld, Winlevi |
| Mission Pharmacal Company | $11,855.78 | 2019 | |
| Dermavant Sciences, INC. | $3,156.76 | 2023-2024 | Vtama |
| Abbvie INC. | $1,645.76 | 2019-2025 | |
| Galderma Laboratories, L.P. | $1,373.40 | 2019-2025 | Nemluvio, Aklief, Twyneo |
| Pfizer INC. | $1,347.92 | 2019-2025 | |
| Journey Medical Corporation | $1,162.62 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,018.50 | 2019-2023 | Jublia, Arazlo |
| Janssen Biotech, INC. | $888.93 | 2019-2025 | Tremfya, Stelara, Simponi |
| E.R. Squibb & Sons, L.L.C. | $769.86 | 2022-2025 | Sotyktu |
| Medimetriks Pharmaceuticals, INC. | $723.84 | 2019-2025 | Clindacin Etz, Neo-Synalar |
| Arcutis Biotherapeutics, INC. | $646.74 | 2023-2025 | Zoryve |
| Genzyme Corporation | $623.86 | 2019-2025 | |
| Ucb, INC. | $598.09 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $549.97 | 2021-2024 | Dupixent |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $543.03 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $452.94 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $415.50 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $385.56 | 2019-2025 | |
| Incyte Corporation | $353.40 | 2021-2025 | Opzelura |
| Amgen INC. | $334.90 | 2020-2025 | Otezla, Enbrel, Otezla |
| Vyne Pharmaceuticals INC. | $243.20 | 2020-2021 | |
| Dermira, INC. | $212.27 | 2019-2021 | |
| Epi Health, LLC | $201.58 | 2019-2022 | |
| Botanix Sb INC | $188.59 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.53 | 2023-2025 | Spevigo |
| Sanofi-Aventis U.S. LLC | $144.00 | 2021-2024 | |
| Apollo Endosurgery US INC | $140.66 | 2023 | Overstitch Endoscopic Suturing System |
| Encore Dermatology INC. | $106.32 | 2019-2020 | |
| Merz North America, INC. | $104.87 | 2023-2025 | Xeomin |
| Almirall LLC | $81.27 | 2019-2024 | Klisyri |
| Organon LLC | $72.22 | 2025 | Vtama, Nexplanon |
| Sebela Pharmaceuticals INC. | $31.67 | 2020 | |
| Sandoz INC. | $23.55 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $19.81 | 2022 | |
| Aclaris Therapeutics, INC. | $18.51 | 2019 | |
| Genentech USA, INC. | $18.50 | 2019 | |
| Celgene Corporation | $16.40 | 2019 | |
| Mylan Pharmaceuticals INC. | $16.07 | 2019 | |
| Merck Sharp & Dohme LLC | $12.00 | 2019 | |
| Biofrontera INC. | $10.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yolanda Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.